MedPlus Health Services Limited has informed stock exchanges about additional regulatory actions taken against its subsidiary company's retail pharmacy operations. The healthcare retailer disclosed that Optival Health Solutions Private Limited, a subsidiary, has now received multiple drug license suspension orders from state drug control authorities across different locations.

Regulatory Actions Across Multiple States

The subsidiary has faced enforcement actions from drug control administrations in Karnataka, Telangana, and Andhra Pradesh. All suspension orders were issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Updated Financial Impact Assessment

The company has quantified the potential financial impact of these regulatory actions. With the latest suspension order received on March 14, 2026, the combined potential revenue loss across all affected stores has increased significantly. The newest Karnataka store suspension at Bidadi Bus stand carries the highest individual financial impact of Rs 2.88 lacs despite being a two-day suspension period.

Latest Regulatory Compliance Disclosure

MedPlus Health Services made the latest disclosure under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company received the most recent suspension order on March 14, 2026, and reported the matter to stock exchanges on March 15, 2026. Company Secretary and Compliance Officer Manoj Kumar Srivastava signed the regulatory filing.

Documentation and Transparency

The company has committed to making complete details available on its official website at www.medplusindia.com . The information will also be accessible through BSE Limited and National Stock Exchange of India websites, ensuring transparency for all stakeholders and regulatory compliance. The latest filing follows SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.

MedPlus Health Services has announced that its subsidiary, Optival Health Solutions Private Limited, has received multiple drug license suspensions from state authorities. The regulatory actions affect stores in Maharashtra and Odisha, representing compliance issues under the Drugs and Cosmetics Act.

Latest Regulatory Action in Odisha

The company received a new suspension order on March 09, 2026, from the Deputy Drugs Controller, Western Zone, Sambalpur, Odisha. This latest action affects a store located opposite the Private Bus Stand in Baragarh, Odisha, with a three-day suspension period.

Previous Maharashtra Suspension

Earlier, the subsidiary had received a seven-day drug license suspension from Maharashtra authorities for a store in Sangvi, Pune. This suspension order was received on March 03, 2026, from the Assistant Commissioner & Licensing Authority, Food & Drug Administration, Maharashtra.

Financial Impact Assessment

The company has quantified the potential revenue losses from both suspensions. The combined financial impact represents the expected business disruption during the suspension periods across both affected locations.

Regulatory Compliance Framework

Both suspensions fall under Rule 65 of the Drugs and Cosmetics Act, 1940, and Drugs and Cosmetics Rules, 1945, which govern pharmaceutical retail operations across India. Such actions by state drug control authorities typically occur when retail pharmacy operations fail to meet specific regulatory requirements or standards.

The company has disclosed this information under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, ensuring transparency with stakeholders regarding regulatory matters affecting its subsidiary operations. The disclosures follow SEBI circulars dated July 13, 2023, and December 31, 2024, regarding regulatory action reporting requirements.